Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

17 November 2016

Access to Medicine Index says industry is making ‘moderate progress’

The Pharmaceutical Journal reports on the industry-level findings from the 2016 Access to Medicine Index, including on progress in pro-access licensing, and the static use of equitable pricing.

A total of 2 billion people worldwide cannot get the medicines they need despite “moderate progress” by the pharmaceutical industry to improve access over the past two years, according to the latest Access to Medicine Index.

The index, funded by the Bill and Melinda Gates Foundation and the UK and Dutch governments, is published every two years and ranks the top 20 global drug companies according to the efforts they make to improve access to drugs in developing countries.

The 2016 index acknowledges improvements in the way access to medicines is organised and says drug companies are investing in developing drugs that are needed most but that this good practice is limited…

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved